{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:28:42Z","timestamp":1759159722399,"version":"3.41.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T00:00:00Z","timestamp":1453248000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s00228-016-2008-2","type":"journal-article","created":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T05:24:28Z","timestamp":1453267468000},"page":"555-562","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy"],"prefix":"10.1007","volume":"72","author":[{"given":"Kazuyuki","family":"Inoue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukitoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,20]]},"reference":[{"key":"2008_CR1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2125.1998.00835.x","volume":"46","author":"RG Morris","year":"1998","unstructured":"Morris RG, Black AB, Harris AL, Batty AB, Sallustio BC (1998) Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. Br J Clin Pharmacol 46:547\u2013551","journal-title":"Br J Clin Pharmacol"},{"key":"2008_CR2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00003088-200645110-00002","volume":"45","author":"SI Johannessen","year":"2006","unstructured":"Johannessen SI, Tomson T (2006) Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 45:1061\u20131075","journal-title":"Clin Pharmacokinet"},{"key":"2008_CR3","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1515\/CCLM.2004.245","volume":"42","author":"HM Neels","year":"2004","unstructured":"Neels HM, Sierens AC, Naelaerts K, Scharp\u00e9 SL, Hatfield GM, Lambert WE (2004) Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 42:1228\u20131255","journal-title":"Clin Chem Lab Med"},{"key":"2008_CR4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","volume":"25","author":"SI Johannessen","year":"2003","unstructured":"Johannessen SI, Battino D, Berry DJ, Bialer M, Kr\u00e4mer G, Tomson T, Patsalos PN (2003) Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 25:347\u2013363","journal-title":"Ther Drug Monit"},{"key":"2008_CR5","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","volume":"34","author":"A Rowland","year":"2006","unstructured":"Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO (2006) In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 34:1055\u20131062","journal-title":"Drug Metab Dispos"},{"key":"2008_CR6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2133\/dmpk.20.144","volume":"20","author":"M Saeki","year":"2005","unstructured":"Saeki M, Saito Y, Jinno H, Sai K, Hachisuka A, Kaniwa N, Ozawa S, Kawamoto M, Kamatani N, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Komamura K, Kotake T, Morishita H, Kamakura S, Kitakaze M, Tomoike H, Sawada J (2005) Genetic variations and haplotypes of UGT1A4 in a Japanese population. Drug Metab Pharmacokinet 20:144\u2013151","journal-title":"Drug Metab Pharmacokinet"},{"key":"2008_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2011.01.016","volume":"95","author":"MI Gulcebi","year":"2011","unstructured":"Gulcebi MI, Ozkaynakc\u0131 A, Goren MZ, Aker RG, Ozkara C, Onat FY (2011) The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res 95:1\u20138","journal-title":"Epilepsy Res"},{"key":"2008_CR8","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0026-895X(24)26503-2","volume":"57","author":"Y Ishii","year":"2000","unstructured":"Ishii Y, Hansen AJ, Mackenzie PI (2000) Octamer transcription factor-1 enhances hepatic nuclear factor-1alpha-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter. Mol Pharmacol 57:940\u2013947","journal-title":"Mol Pharmacol"},{"key":"2008_CR9","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00228-012-1449-5","volume":"69","author":"N Singkham","year":"2013","unstructured":"Singkham N, Towanabut S, Lertkachatarn S, Punyawudho B (2013) Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients. Eur J Clin Pharmacol 69:1285\u20131291","journal-title":"Eur J Clin Pharmacol"},{"key":"2008_CR10","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.dmpk.2015.01.001","volume":"30","author":"Y Yamamoto","year":"2015","unstructured":"Yamamoto Y, Takahashi Y, Imai K, Ikeda H, Takahashi M, Nakai M, Inoue Y, Kagawa Y (2015) Influence of uridine diphosphate glucuronosyltransferase inducers and inhibitors on the plasma lamotrigine concentration in pediatric patients with refractory epilepsy. Drug Metab Pharmacokinet 30:214\u2013220","journal-title":"Drug Metab Pharmacokinet"},{"key":"2008_CR11","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1212\/WNL.55.4.588","volume":"55","author":"AM Kanner","year":"2000","unstructured":"Kanner AM, Frey M (2000) Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology 55:588\u2013591","journal-title":"Neurology"},{"key":"2008_CR12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00007691-199610000-00001","volume":"18","author":"TW May","year":"1996","unstructured":"May TW, Rambeck B, J\u00fcrgens U (1996) Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit 18:523\u2013531","journal-title":"Ther Drug Monit"},{"key":"2008_CR13","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00228-015-1925-9","volume":"71","author":"L Liu","year":"2015","unstructured":"Liu L, Zhao L, Wang Q, Qiu F, Wu X, Ma Y (2015) Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C>T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children. Eur J Clin Pharmacol 71:1341\u20131347","journal-title":"Eur J Clin Pharmacol"},{"key":"2008_CR14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/bmj.2.5402.177","volume":"2","author":"PP Rickham","year":"1964","unstructured":"Rickham PP (1964) Human experimentation. Code of ethics of the World Medical Association. Declaration of Helsinki. Br Med J 2:177","journal-title":"Br Med J"},{"key":"2008_CR15","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0090-9556(24)02990-8","volume":"32","author":"M Saeki","year":"2004","unstructured":"Saeki M, Saito Y, Jinno H, Tanaka-Kagawa T, Ohno A, Ozawa S, Ueno K, Kamakura S, Kamatani N, Komamura K, Kitakaze M, Sawada J (2004) Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab Dispos 32:1048\u20131054","journal-title":"Drug Metab Dispos"},{"key":"2008_CR16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clinbiochem.2006.01.002","volume":"39","author":"K Saito","year":"2006","unstructured":"Saito K, Moriya H, Sawaguchi T, Hayakawa T, Nakahara S, Goto A, Arimura Y, Imai K, Kurosawa N, Owada E, Miyamoto A (2006) Haplotype analysis of UDP-glucuronocyltransferase 2B7 gene (UGT2B7) polymorphisms in healthy Japanese subjects. Clin Biochem 39:303\u2013308","journal-title":"Clin Biochem"},{"key":"2008_CR17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FTD.0b013e3181ceecc6","volume":"32","author":"M Blanca S\u00e1nchez","year":"2010","unstructured":"Blanca S\u00e1nchez M, Herranz JL, Leno C, Arteaga R, Oterino A, Valdiz\u00e1n EM, Nicolas JM, Ad\u00edn J, Shushtarian M, Armijo JA (2010) UGT2B7 -161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study. Ther Drug Monit 32:177\u2013184","journal-title":"Ther Drug Monit"},{"key":"2008_CR18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/gut.50.2.259","volume":"50","author":"CP Strassburg","year":"2002","unstructured":"Strassburg CP, Strassburg A, Kneip S, Barut A, Tukey RH, Rodeck B, Manns MP (2002) Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 50:259\u2013265","journal-title":"Gut"},{"key":"2008_CR19","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1124\/dmd.107.015214","volume":"35","author":"SJ Miyagi","year":"2007","unstructured":"Miyagi SJ, Collier AC (2007) Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4. Drug Metab Dispos 35:1587\u20131592","journal-title":"Drug Metab Dispos"},{"key":"2008_CR20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.yebeh.2013.07.016","volume":"29","author":"I Wegner","year":"2013","unstructured":"Wegner I, Wilhelm AJ, Sander JW, Lindhout D (2013) The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study. Epilepsy Behav 29:217\u2013221","journal-title":"Epilepsy Behav"},{"key":"2008_CR21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/FTD.0000000000000158","volume":"37","author":"GS Naik","year":"2015","unstructured":"Naik GS, Kodagali R, Mathew BS, Thomas M, Prabha R, Mathew V, Fleming DH (2015) Therapeutic drug monitoring of levetiracetam and lamotrigine: is there a need? Ther Drug Monit 37:437\u2013444","journal-title":"Ther Drug Monit"},{"key":"2008_CR22","doi-asserted-by":"crossref","unstructured":"Reimers A, Sjursen W, Helde G, Brodtkorb E (2014) Frequencies of UGT1A4*2 (P24T) and *3 (L48V) and their effects on serum concentrations of lamotrigine. Eur J Drug Metab Pharmacokinet","DOI":"10.1007\/s13318-014-0247-0"},{"key":"2008_CR23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.dmpk.2014.12.007","volume":"30","author":"Q Wang","year":"2015","unstructured":"Wang Q, Liang M, Dong Y, Yun W, Qiu F, Zhao L, Guo Y (2015) Effects of UGT1A4 genetic polymorphisms on serum lamotrigine concentrations in Chinese children with epilepsy. Drug Metab Pharmacokinet 30:209\u2013213","journal-title":"Drug Metab Pharmacokinet"},{"key":"2008_CR24","first-page":"101","volume":"9","author":"Y Takekuma","year":"2006","unstructured":"Takekuma Y, Takenaka T, Kiyokawa M, Yamazaki K, Okamoto H, Kitabatake A, Tsutsui H, Sugawara M (2006) Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol. J Pharm Pharm Sci 9:101\u2013112","journal-title":"J Pharm Pharm Sci"},{"key":"2008_CR25","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1248\/bpb.30.537","volume":"30","author":"Y Takekuma","year":"2007","unstructured":"Takekuma Y, Takenaka T, Kiyokawa M, Yamazaki K, Okamoto H, Kitabatake A, Tsutsui H, Sugawara M (2007) Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis. Biol Pharm Bull 30:537\u2013542","journal-title":"Biol Pharm Bull"},{"key":"2008_CR26","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1345\/aph.17332","volume":"32","author":"GD Anderson","year":"1998","unstructured":"Anderson GD (1998) A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 32:554\u2013563","journal-title":"Ann Pharmacother"},{"key":"2008_CR27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","volume":"2","author":"PN Patsalos","year":"2003","unstructured":"Patsalos PN, Perucca E (2003) Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2:347\u2013356","journal-title":"Lancet Neurol"},{"key":"2008_CR28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1248\/bpb.35.487","volume":"35","author":"Y Yamamoto","year":"2012","unstructured":"Yamamoto Y, Inoue Y, Matsuda K, Takahashi Y, Kagawa Y (2012) Influence of concomitant antiepileptic drugs on plasma lamotrigine concentration in adult Japanese epilepsy patients. Biol Pharm Bull 35:487\u2013493","journal-title":"Biol Pharm Bull"},{"key":"2008_CR29","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40262-013-0087-0","volume":"52","author":"PN Patsalos","year":"2013","unstructured":"Patsalos PN (2013) Drug interactions with the newer antiepileptic drugs (AEDs)\u2014part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet 52:927\u2013966","journal-title":"Clin Pharmacokinet"},{"key":"2008_CR30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/ern.09.136","volume":"10","author":"C Johannessen Landmark","year":"2010","unstructured":"Johannessen Landmark C, Patsalos PN (2010) Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother 10:119\u2013140","journal-title":"Expert Rev Neurother"},{"key":"2008_CR31","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1528-1167.2008.01665.x","volume":"49","author":"E Perucca","year":"2008","unstructured":"Perucca E, Cloyd J, Critchley D, Fuseau E (2008) Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 49:1123\u20131141","journal-title":"Epilepsia"},{"key":"2008_CR32","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.jcp.0000169418.31275.a7","volume":"25","author":"A Reimers","year":"2005","unstructured":"Reimers A, Skogvoll E, Sund JK, Spigset O (2005) Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J Clin Psychopharmacol 25:342\u2013348","journal-title":"J Clin Psychopharmacol"},{"key":"2008_CR33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2125.2005.02539.x","volume":"61","author":"J Sidhu","year":"2006","unstructured":"Sidhu J, Job S, Singh S, Philipson R (2006) The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol 61:191\u2013199","journal-title":"Br J Clin Pharmacol"},{"key":"2008_CR34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0920-1211(01)00305-9","volume":"47","author":"A Sabers","year":"2001","unstructured":"Sabers A, Buchholt JM, Uldall P, Hansen EL (2001) Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 47:151\u2013154","journal-title":"Epilepsy Res"},{"key":"2008_CR35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S2213-8587(14)70081-6","volume":"3","author":"RM Paragliola","year":"2015","unstructured":"Paragliola RM, Prete A, Kaplan PW, Corsello SM, Salvatori R (2015) Treatment of hypopituitarism in patients receiving antiepileptic drugs. Lancet Diabetes Endocrinol 3:132\u2013140","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2008_CR36","first-page":"659","volume":"121","author":"C Sharma","year":"2005","unstructured":"Sharma C, Dubey R, Kumar H, Saha N (2005) Food reduces the bioavailability of lamotrigine. Indian J Med Res 121:659\u2013664","journal-title":"Indian J Med Res"},{"key":"2008_CR37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/ane.12330","volume":"131","author":"M Kverneland","year":"2015","unstructured":"Kverneland M, Taub\u00f8ll E, Selmer KK, Iversen PO, Nakken KO (2015) Modified Atkins diet may reduce serum concentrations of antiepileptic drugs. Acta Neurol Scand 131:187\u2013190","journal-title":"Acta Neurol Scand"},{"key":"2008_CR38","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.seizure.2008.05.009","volume":"17","author":"C Reinsberger","year":"2008","unstructured":"Reinsberger C, Dorn T, Kr\u00e4mer G (2008) Smoking reduces serum levels of lamotrigine. Seizure 17:651\u2013653","journal-title":"Seizure"},{"key":"2008_CR39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00002018-199309010-00003","volume":"9","author":"GM Shenfield","year":"1993","unstructured":"Shenfield GM (1993) Oral contraceptives. Are drug interactions of clinical significance? Drug Saf 9:21\u201337","journal-title":"Drug Saf"},{"key":"2008_CR40","first-page":"1785","volume":"124","author":"A Reimers","year":"2004","unstructured":"Reimers A (2004) Oral contraceptives can affect the metabolism of other drugs. Tidsskr Nor Laegeforen 124:1785\u20131787","journal-title":"Tidsskr Nor Laegeforen"},{"key":"2008_CR41","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1684\/epd.2014.0714","volume":"16","author":"G Zaccara","year":"2014","unstructured":"Zaccara G, Perucca E (2014) Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord 16:409\u2013431","journal-title":"Epileptic Disord"},{"key":"2008_CR42","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","volume":"61","author":"E Perucca","year":"2006","unstructured":"Perucca E (2006) Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61:246\u2013255","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"2008_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199700321-00003","volume":"32","author":"SH Preskorn","year":"1997","unstructured":"Preskorn SH (1997) Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 32(Suppl 1):1\u201321","journal-title":"Clin Pharmacokinet"},{"key":"2008_CR44","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1034\/j.1399-6576.2003.00036.x","volume":"47","author":"H Pleym","year":"2003","unstructured":"Pleym H, Spigset O, Kharasch ED, Dale O (2003) Gender differences in drug effects: implications for anesthesiologists. Acta Anaesthesiol Scand 47:241\u2013259","journal-title":"Acta Anaesthesiol Scand"},{"key":"2008_CR45","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/0920-1211(87)90041-6","volume":"1","author":"S Jawad","year":"1987","unstructured":"Jawad S, Yuen WC, Peck AW, Hamilton MJ, Oxley JR, Richens A (1987) Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1:194\u2013201","journal-title":"Epilepsy Res"},{"key":"2008_CR46","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/clpt.1987.193","volume":"42","author":"AF Cohen","year":"1987","unstructured":"Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW (1987) Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 42:535\u2013541","journal-title":"Clin Pharmacol Ther"},{"key":"2008_CR47","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1528-1157.1996.tb00650.x","volume":"37","author":"AS Eriksson","year":"1996","unstructured":"Eriksson AS, Hoppu K, Nerg\u00e5rdh A, Boreus L (1996) Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. Epilepsia 37:769\u2013773","journal-title":"Epilepsia"},{"key":"2008_CR48","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/pds.1690","volume":"18","author":"A Reimers","year":"2009","unstructured":"Reimers A (2009) Trends and changes in the clinical use of lamotrigine. Pharmacoepidemiol Drug Saf 18:132\u2013139","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2008_CR49","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.seizure.2007.11.023","volume":"17","author":"M S\u00f8ndergaard Khinchi","year":"2008","unstructured":"S\u00f8ndergaard Khinchi M, Nielsen KA, Dahl M, Wolf P (2008) Lamotrigine therapeutic thresholds. Seizure 17:391\u2013395","journal-title":"Seizure"},{"key":"2008_CR50","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2147\/TCRM.S3343","volume":"4","author":"MA Werz","year":"2008","unstructured":"Werz MA (2008) Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release. Ther Clin Risk Manag 4:1035\u20131046","journal-title":"Ther Clin Risk Manag"},{"key":"2008_CR51","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/FTD.0b013e31817fd4d4","volume":"30","author":"N Rivas","year":"2008","unstructured":"Rivas N, Buelga DS, Elger CE, Santos-Borbujo J, Otero MJ, Dom\u00ednguez-Gil A, Garc\u00eda MJ (2008) Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. Ther Drug Monit 30:483\u2013489","journal-title":"Ther Drug Monit"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2008-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-016-2008-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2008-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T05:20:56Z","timestamp":1748755256000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-016-2008-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,20]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["2008"],"URL":"https:\/\/doi.org\/10.1007\/s00228-016-2008-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2016,1,20]]}}}